Design, synthesis and biological evaluation of 1H-pyrrolo[2,3-b]pyridine and 1H-pyrazolo[3,4-b]pyridine derivatives as c-Met inhibitors
- 1 April 2016
- journal article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 65, 146-158
Abstract
No abstract availableKeywords
Funding Information
- IRM-CAMS Research Fund (1531)
- Binjiang Pharma, Inc
This publication has 12 references indexed in Scilit:
- Design and Optimization of a Series of 1-Sulfonylpyrazolo[4,3-b]pyridines as Selective c-Met InhibitorsJournal of Medicinal Chemistry, 2015
- Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical ProgressJournal of Medicinal Chemistry, 2013
- c-MET kinase inhibitors: a patent review (2011 – 2013)Expert Opinion on Therapeutic Patents, 2013
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- Discovery of Small Molecule c-Met Inhibitors: Evolution and Profiles of Clinical CandidatesAnti-Cancer Agents in Medicinal Chemistry, 2010
- Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitorsBioorganic & Medicinal Chemistry Letters, 2008
- c-Met as a target for human cancer and characterization of inhibitors for therapeutic interventionCancer Letters, 2005
- Hepatocyte growth factor, its receptor, and their potential value in cancer therapiesCritical Reviews in Oncology/Hematology, 2005
- c-Met: Structure, functions and potential for therapeutic inhibitionCancer and Metastasis Reviews, 2003
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003